<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940627-0-00244</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4700 -->  <!-- PJG ITAG l=11 g=1 f=1 --> (iii) Any animal which dies during the test is necropsied  <!-- PJG 0012 frnewline --> as soon as possible after discovery.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (5)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Clinical examinations. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  (i) The following examinations shall be performed on the  <!-- PJG 0012 frnewline --> twenty animals designated as the 90-day study population,  <!-- PJG 0012 frnewline --> exclusive of pregnant dams and those study animals targeted for  <!-- PJG 0012 frnewline --> perfusion by gravity:  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (A) The following hematology determinations shall be  <!-- PJG 0012 frnewline --> carried out at least two times during the test period (after 30  <!-- PJG 0012 frnewline --> days of exposure and just prior to terminal sacrifice at the end  <!-- PJG 0012 frnewline --> of the exposure period): hematocrit, hemoglobin concentration,  <!-- PJG 0012 frnewline --> erythrocyte count, total and differential leukocyte count, and a  <!-- PJG 0012 frnewline --> measure of clotting potential such as prothrombin time,  <!-- PJG 0012 frnewline --> thromboplastin time, or platelet count.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (B) Clinical biochemistry determinations on blood shall be  <!-- PJG 0012 frnewline --> carried out at least two times during the test period, after 30  <!-- PJG 0012 frnewline --> days of exposure and just prior to terminal sacrifice at the end  <!-- PJG 0012 frnewline --> of the exposure period, on all groups of animals including  <!-- PJG 0012 frnewline --> concurrent controls. Clinical biochemical testing shall include  <!-- PJG 0012 frnewline --> assessment of electrolyte balance, carbohydrate metabolism, and  <!-- PJG 0012 frnewline --> liver and kidney function. The selection of specific tests will  <!-- PJG 0012 frnewline --> be influenced by observations on the mode of action of the  <!-- PJG 0012 frnewline --> substance. In the absence of more specific tests, the following  <!-- PJG 0012 frnewline --> determinations may be made: calcium, phosphorus, chloride,  <!-- PJG 0012 frnewline --> sodium, potassium, fasting glucose (with period of fasting  <!-- PJG 0012 frnewline --> appropriate to the species), serum alanine aminotransferase,  <!-- PJG 0012 frnewline --> serum aspartate aminotransferase, sorbitol dehydrogenase, gamma  <!-- PJG 0012 frnewline --> glutamyl transpeptidase, urea nitrogen, albumen, blood  <!-- PJG 0012 frnewline --> creatinine, methemoglobin, bile acids, total bilirubin, and total  <!-- PJG 0012 frnewline --> serum protein measurements. Additional clinical biochemistry  <!-- PJG 0012 frnewline --> shall be employed, where necessary, to extend the investigation  <!-- PJG 0012 frnewline --> of observed effects, e.g., analyses of lipids, hormones, acid/base  <!-- PJG 0012 frnewline --> balance, and cholinesterase activity.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (ii) The following examinations shall initially be  <!-- PJG 0012 frnewline --> performed on the high concentration and control groups only:  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (A) Ophthalmological examination, using an ophthalmoscope  <!-- PJG 0012 frnewline --> or equivalent suitable equipment, shall be made prior to exposure  <!-- PJG 0012 frnewline --> to the test substance and at the termination of the study. If  <!-- PJG 0012 frnewline --> changes in the eyes are detected, all animals shall be examined.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (B) Urinalysis is not required on a routine basis, but  <!-- PJG 0012 frnewline --> shall be done when there is an indication based on expected  <!-- PJG 0012 frnewline --> and/or observed toxicity.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (iii) Preservation by whole-body perfusion of fixative into  <!-- PJG 0012 frnewline --> the anaesthetized animal for lung histology of ten animals from  <!-- PJG 0012 frnewline --> the 90-day study population for each experimental and control  <!-- PJG 0012 frnewline --> group.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (6)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Gross pathology.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> With the exception of the whole body  <!-- PJG 0012 frnewline --> perfusion-fixed test animals cited in paragraph (d)(1)(ii)(A) of  <!-- PJG 0012 frnewline --> this section, all rodents shall be subjected to a full gross  <!-- PJG 0012 frnewline --> necropsy which includes examination of the external surface of  <!-- PJG 0012 frnewline --> the body, all orifices and the cranial, thoracic, and abdominal  <!-- PJG 0012 frnewline --> cavities and their contents. Gross pathology shall be performed  <!-- PJG 0012 frnewline --> on the following organs and tissues:  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (i) The liver, kidneys, lungs, adrenals, brain, and gonads,  <!-- PJG 0012 frnewline --> including uterus, ovaries, testes, epididymides, seminal vesicles  <!-- PJG 0012 frnewline --> (with coagulating glands), and prostate, constitute the group of  <!-- PJG 0012 frnewline --> target organs for histology and shall be weighed as soon as  <!-- PJG 0012 frnewline --> possible after dissection to avoid drying. In addition, for  <!-- PJG 0012 frnewline --> other than rodent test species, the thyroid with parathyroids,  <!-- PJG 0012 frnewline --> when present, shall also be weighed as soon as possible after  <!-- PJG 0012 frnewline --> dissection to avoid drying.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (ii) The following organs and tissues, or representative  <!-- PJG 0012 frnewline --> samples thereof, shall be preserved in a suitable medium for  <!-- PJG 0012 frnewline --> possible future histopathological examination: All gross lesions;  <!-- PJG 0012 frnewline --> lungs_which shall be removed intact, weighed, and treated with  <!-- PJG 0012 frnewline --> a suitable fixative to ensure that lung structure is maintained  <!-- PJG 0012 frnewline --> (perfusion with the fixative is considered to be an effective  <!-- PJG 0012 frnewline --> procedure); nasopharyngeal tissues; brain_including sections of  <!-- PJG 0012 frnewline --> medulla/pons, cerebellar cortex, and cerebral cortex; pituitary;  <!-- PJG 0012 frnewline --> thyroid/parathyroid; thymus; trachea; heart; sternum with bone  <!-- PJG 0012 frnewline --> marrow; salivary glands; liver; spleen; kidneys; adrenals;  <!-- PJG 0012 frnewline --> pancreas; reproductive organs: uterus; cervix; ovaries; vagina;  <!-- PJG 0012 frnewline --> testes; epididymides; prostate; and, if present, seminal  <!-- PJG 0012 frnewline --> vesicles; aorta; (skin); gall bladder (if present); esophagus;  <!-- PJG 0012 frnewline --> stomach; duodenum; jejunum; ileum; cecum; colon; rectum; urinary  <!-- PJG 0012 frnewline --> bladder; representative lymph node; (mammary gland); (thigh  <!-- PJG 0012 frnewline --> musculature); peripheral nerve/tissue; (eyes); (femur_including  <!-- PJG 0012 frnewline --> articular surface); (spinal cord at three levels_cervical,  <!-- PJG 0012 frnewline --> midthoracic, and lumbar); and (zymbal and exorbital lachrymal  <!-- PJG 0012 frnewline --> glands).  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (7)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Histopathology.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Histopathology shall be performed on  <!-- PJG 0012 frnewline --> the following organs and tissues from all rodents:  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (i) All gross lesions.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (ii) Respiratory tract and other organs and tissues, listed  <!-- PJG 0012 frnewline --> in paragraph (d)(6)(ii) of this section (except organs/tissues in  <!-- PJG 0012 frnewline --> parentheses), of all animals in the control and high dose groups.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (iii) The tissues mentioned in parentheses, listed in  <!-- PJG 0012 frnewline --> paragraph (d)(6)(ii) of this section, if indicated by signs of  <!-- PJG 0012 frnewline --> toxicity or target organ involvement.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (iv) Lungs of animals in the low and intermediate dose  <!-- PJG 0012 frnewline --> groups shall also be subjected to histopathological examination,  <!-- PJG 0012 frnewline --> primarily for evidence of infection since this provides a  <!-- PJG 0012 frnewline --> convenient assessment of the state of health of the animals.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            